证券代码：300039 证券简称：上海凯宝 记录编号：2017-004 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|------------------------|-------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | --- | --- | |----------|------------------------------------------------------------------| | | | | 参与单位 | | | 名称及人 | 凯峰资本 | | 员姓名 | | | 时 间 | 2017 年 9 月 25 日 下午 2： 30 -4：00 | | 地 点 | 公司二楼会议室 | | 上市公司 | | | 接待人员 | 董 秘：穆竟伟 证券部：马聪 ...

证券代码：300039 证券简称：上海凯宝 记录编号：2017-003 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|-------------------------|------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系 | □ | 新闻发布会 □路演活动 | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | | | | 参与单位 | | | | 名称及人 | | 中金公司、财通证券、承珞资本、 | | 员姓名 | | | | 时 间 | 2017 年 8 月 23 | 日 上午 10： 30 -12：00 | | 地 点 | 公司二楼会议室 | | | 上市公司 | | | | 接待人员 | | 董 秘：穆竟伟 证券部：马聪影 | | 姓名 | | | | 投资者关 | | 一、董秘穆竟伟女士简单介绍公司基本情况 | | ...

Financial Performance - The company's revenue for Q3 2022 was ¥259,841,333.60, representing a 1.14% increase year-over-year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥35,835,359.96, up 6.31% compared to the same period last year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥34,405,017.31, reflecting a significant increase of 21.88% year-over-year[7]. - Total operating revenue for the current period reached ¥800,013,064.85, a slight increase from ¥794,949,444.36 in the previous period, representing a growth of approximately 1.34%[30]. - Net profit for the current period was ¥118,044,013.52, compared to ¥115,498,710.67 in the previous period, indicating an increase of approximately 2.14%[30]. - Other comprehensive income after tax for the current period was ¥585,310,000.00, compared to ¥373,137,500.00 in the previous period, reflecting an increase of approximately 56.8%[32]. - The total comprehensive income for the current period was ¥703,354,013.52, compared to ¥488,636,210.67 in the previous period, indicating a growth of about 43.9%[32]. Cash Flow and Investments - The operating cash flow net amount for the year-to-date period increased by 129.99%, totaling ¥236,316,100.08[7]. - Net cash flow from operating activities decreased by 135.05% year-over-year, mainly due to increased investment activities[16]. - Cash inflow from operating activities totaled ¥1,008,773,655.28, up from ¥963,717,206.74, representing an increase of approximately 4.7%[33]. - Cash inflow from investment activities totaled $2.47 billion, compared to $1.46 billion in the prior period, indicating strong investment recovery[36]. - Net cash outflow from investment activities was $197.78 million, a decline from a positive cash flow of $3.72 million previously, suggesting increased investment expenditures[36]. - Cash inflow from the recovery of investments was $2.07 billion, significantly higher than $1.32 billion in the previous period, highlighting effective investment strategies[36]. - The company made cash payments for investments totaling $2.13 billion, compared to $1.31 billion previously, indicating aggressive investment in growth opportunities[36]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,156,931,861.21, a 23.87% increase from the end of the previous year[7]. - The company's total current assets as of September 30, 2022, amount to CNY 2,357,412,713.73, an increase from CNY 2,254,417,970.03 at the beginning of the year[21]. - The total non-current assets increased to CNY 1,799,519,147.48 from CNY 1,101,398,799.74[24]. - The total liabilities increased to ¥460,966,028.56 from ¥310,904,950.64, showing a significant rise of approximately 48.3%[30]. - The total liabilities include short-term borrowings of CNY 81,910,127.65 and accounts payable of CNY 75,015,901.66[24]. Shareholder Information - Shareholders' equity attributable to the parent company was ¥3,696,536,519.48, marking a 21.40% increase compared to the previous year[7]. - The total number of common shareholders at the end of the reporting period is 58,608, with the top ten shareholders holding significant stakes[17]. - The largest shareholder, Mu Jingwei, holds 16.06% of the shares, amounting to 168,029,270 shares[17]. Operational Costs and Expenses - Total operating costs decreased to ¥660,043,298.28 from ¥663,967,428.89, reflecting a reduction of about 0.44%[30]. - Research and development expenses rose to ¥36,092,230.66 from ¥31,986,225.60, marking an increase of about 12.6%[30]. - The company paid $173.05 million to employees, an increase from $162.09 million, reflecting higher operational costs[36]. - Cash outflow related to other operating activities was $370.61 million, down from $408.61 million, showing improved cost management[36]. Government Support - The company received government subsidies amounting to ¥3,159,357.91 during the reporting period[8]. Miscellaneous - The company has not disclosed any new strategies or future outlook in the provided documents[19].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥540,171,731.25, representing a 0.40% increase compared to the same period last year[27]. - The net profit attributable to shareholders for the same period was ¥82,777,022.64, reflecting a 1.21% increase year-on-year[27]. - The net cash flow from operating activities increased significantly by 60.04%, reaching ¥135,594,349.20[27]. - Total assets at the end of the reporting period amounted to ¥4,958,543,477.72, a 47.76% increase from the end of the previous year[27]. - The net assets attributable to shareholders increased by 44.96% to ¥4,413,843,659.52[27]. - Basic earnings per share for the reporting period were ¥0.0791, up 1.15% from the previous year[27]. - The weighted average return on net assets decreased to 2.20%, down 0.93% compared to the same period last year[27]. - Operating costs increased by 15.92% to ¥122,445,859.14 from ¥105,631,636.32 in the previous year[71]. - The gross profit margin for injections is 83.56%, with a year-on-year decrease of 0.48%[75]. Market and Product Development - The company is focused on expanding its market presence and developing new products and technologies[27]. - The company focuses on modern traditional Chinese medicine R&D, production, and sales, with key product lines in respiratory, cardiovascular, and digestive health[36]. - The company has established a comprehensive procurement, R&D, production, and sales system to meet market demands and operational goals[38]. - The company emphasizes a combination of production, learning, and research, collaborating with institutions like Shanghai Jiao Tong University for innovative product development[40]. - The company is advancing the research and development of its main product, Tanreqing, and its series, with ongoing clinical evidence studies[52]. - The company is developing a new 5ml specification for Tanreqing injection, aimed at optimizing product structure[54]. - The company is committed to developing a series of health products supported by its technological accumulation and research in traditional Chinese medicine[62]. - The company is enhancing its market layout in the health sector, aligning with national health strategies[62]. Investment and Funding - The total investment amount for the current period is ¥17,368,421.00, marking a 100% increase compared to the previous year[85]. - The total amount of raised funds is RMB 973.76 million, with RMB 29.7 million invested during the reporting period[87]. - Cumulative investment of raised funds reached RMB 979.05 million by June 30, 2022[92]. - The company plans to use RMB 2,915.91 million of remaining raised funds and interest for the construction of a new R&D building[91]. - The company has invested RMB 13.13 million to acquire 20% equity in Shanghai Yizhong Pharmaceutical Co., Ltd.[91]. - The company has made significant progress in utilizing raised funds for various projects, ensuring effective capital allocation[102]. Risk Management - The company has outlined potential risks and corresponding countermeasures in its management discussion section[5]. - The company acknowledges risks in new drug development, including high investment, long cycles, and potential market changes that could lead to increased costs or project failures[127]. - The company plans to manage R&D risks through various collaborative approaches, optimizing project management, and strengthening the R&D team to ensure successful new drug development[127]. - Raw material prices are subject to fluctuations due to various factors, which can impact profitability; the company will enhance supply chain management to control procurement costs[128]. - The company is closely monitoring industry policy risks, particularly in the pharmaceutical sector, which is heavily influenced by government regulations[125]. Corporate Governance and Compliance - The company has not engaged in derivative investments during the reporting period[117]. - The company has not made any significant asset or equity sales during the reporting period[121]. - The company has no outstanding entrusted loans as of the reporting period[120]. - The company maintained a good integrity status with no unfulfilled court judgments or significant overdue debts[161]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[154]. - There were no violations regarding external guarantees during the reporting period[155]. Social Responsibility - The company actively participated in pandemic prevention efforts, donating approximately CNY 1.2 million worth of products and emergency supplies[51]. - The company donated a total of 150,000 yuan to New Leaf Village and 50,000 yuan to the Shanghai Bay Tourism Area Charity Fund during the reporting period[149]. - The company has not experienced any administrative penalties related to environmental issues during the reporting period[149]. Shareholder Information - The total number of shares before the change was 1,046,000,000, with a 100% ownership ratio[192]. - The largest shareholder, Mu Jingwei, holds 16.06% of the shares, totaling 168,029,270 shares[198]. - The company has a total of 64,324 shareholders at the end of the reporting period[195].

Financial Performance - The company's revenue for Q1 2022 was CNY 343,817,802.76, representing a 1.15% increase compared to CNY 339,907,427.57 in the same period last year[4] - Net profit attributable to shareholders was CNY 57,636,350.93, a 0.70% increase from CNY 57,237,236.12 year-on-year[4] - Total operating revenue for Q1 2022 was CNY 343,817,802.76, a slight increase from CNY 339,907,427.57 in Q1 2021[29] - Net profit for Q1 2022 was CNY 57,142,663.02, showing a marginal decrease from CNY 57,237,236.12 in Q1 2021[32] - Total comprehensive income attributable to the parent company's owners was ¥165,979,475.93, compared to ¥57,237,236.12 in the previous period, indicating significant growth[35] Cash Flow - The net cash flow from operating activities increased by 514.45%, reaching CNY 87,056,121.17, compared to a negative cash flow of CNY -21,005,200.21 in the previous year[4] - Cash inflow from operating activities totaled ¥427,893,178.34, up from ¥325,874,682.61 year-over-year[39] - Cash outflow for operating activities was ¥340,837,057.17, slightly decreased from ¥346,879,882.82 in the previous period[39] - The company reported a net increase in cash and cash equivalents of ¥12,081,417.09, contrasting with a decrease of -¥33,917,259.71 in the previous period[42] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,622,340,110.74, up 7.94% from CNY 3,355,816,769.77 at the end of the previous year[4] - The company's total current assets increased to approximately 2.39 billion yuan, up from 2.25 billion yuan at the beginning of the year, reflecting a growth of about 5.5%[22] - Total liabilities rose to CNY 411,942,503.59, up from CNY 310,904,950.64 in the previous year[28] - The company's total liabilities increased, with accounts payable rising by 58.59% due to increased material costs[9] Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,262, with the largest shareholder, Mu Jingwei, holding 16.06% of shares, equating to 168,029,270 shares[14] - The total number of restricted shares at the end of the reporting period is 129,441,631, with no new restrictions added during the period[18] Research and Development - Research and development expenses decreased by 40.86% compared to the previous year, reflecting a focus on project-based investment[10] - Research and development expenses for Q1 2022 were CNY 10,017,656.02, down from CNY 16,939,440.85 in Q1 2021[29] Investment Activities - The company reported a 63.01% decrease in investment income compared to the previous year, primarily due to reduced returns from bank wealth management products[10] - The company’s subsidiary, Shanghai Kaibao Equity Investment Co., Ltd., increased its investment in Chongqing Jize Biotechnology Co., Ltd. to hold 33% of its registered capital, focusing on the development of new food raw materials[19] - Total cash inflow from investment activities was ¥686,319,148.60, an increase from ¥558,424,293.00 year-over-year[39] Other Financial Metrics - The company's weighted average return on equity increased to 5.31%, up 3.11 percentage points from 2.20% in the same period last year[4] - The company received government subsidies amounting to CNY 1,535,647.80 during the reporting period[5] - The company reported a tax expense of CNY 11,338,642.90 for Q1 2022, compared to CNY 10,860,538.69 in the same period last year[32] - Other comprehensive income after tax for Q1 2022 was CNY 108,343,125.00, all attributable to the parent company's shareholders[32]

Financial Performance - The company reported a total revenue of RMB 1,046 million for the year 2021, representing a year-on-year increase of 15% compared to 2020[6]. - The net profit attributable to shareholders was RMB 150 million, which is a 10% increase from the previous year[6]. - The company's operating revenue for 2021 was ¥1,100,578,391.34, representing a 21.21% increase compared to ¥908,008,861.43 in 2020[25]. - The net profit attributable to shareholders for 2021 was ¥140,113,625.43, a 32.03% increase from ¥106,122,746.60 in 2020[25]. - The net profit after deducting non-recurring gains and losses was ¥125,934,898.50, up 31.63% from ¥95,675,418.53 in the previous year[25]. - The company's cash flow from operating activities decreased by 49.70% to ¥126,078,156.45 from ¥250,649,879.39 in 2020[25]. - The total assets at the end of 2021 were ¥3,355,816,769.77, an increase of 16.63% from ¥2,877,284,200.91 at the end of 2020[25]. - The net assets attributable to shareholders at the end of 2021 were ¥3,044,914,136.88, an 18.10% increase from ¥2,578,324,384.13 at the end of 2020[25]. - The basic earnings per share for 2021 was ¥0.1340, reflecting a 32.02% increase from ¥0.1015 in 2020[25]. - The weighted average return on equity for 2021 was 17.71%, significantly up from 4.05% in 2020[25]. Market Expansion and Product Development - The company plans to distribute a cash dividend of RMB 0.50 per 10 shares, totaling approximately RMB 52.3 million[6]. - The company is focusing on expanding its product line, with plans to launch three new drugs in 2022, targeting a market size of RMB 1 billion[6]. - User data indicates a 20% increase in the number of active users of the company's products, reaching 1.2 million by the end of 2021[6]. - Market expansion efforts include entering two new provinces in China, aiming for a 25% increase in market share by the end of 2022[6]. - Future guidance estimates a revenue growth of 18% for 2022, driven by new product launches and market expansion[6]. - The company is actively seeking new product introductions and acquisitions to expand its product line by leveraging research institutions' resources[154]. - The company is focusing on optimizing its product structure through various new drug research projects, including "痰热清" injection and oral solutions[61]. - The company is enhancing its R&D capabilities and accelerating the development of new products, aiming for a diversified product lineup[154]. Research and Development - The company has allocated RMB 100 million for research and development in new technologies and products for the upcoming year[6]. - The company has formed a joint R&D center with Shanghai Jiao Tong University to enhance collaboration in technology development and production[46]. - The company emphasizes innovation and has established a modernized R&D building to support new product development and attract research talent[51]. - The company obtained 4 invention patents, 5 design patents, and 11 utility model patents during the reporting period, enhancing its intellectual property protection[59]. - The company is conducting clinical research on "痰热清" for treating COVID-19, which has received recognition as an outstanding project in Shanghai[56]. - The company is conducting Phase III clinical trials for the new drug Dinggui Oil Soft Capsule, aimed at treating irritable bowel syndrome[91]. - The company is also in Phase III clinical trials for the new drug Phlegm Heat Clear Oral Liquid, targeting respiratory diseases[94]. Risk Management and Challenges - The company has identified potential risks in regulatory changes and market competition, with strategies in place to mitigate these risks[6]. - The company faces industry risks due to government policies affecting the pharmaceutical sector, which may impact operational performance[153]. - New drug development carries high investment, long cycles, and significant risks, which could adversely affect profitability and future growth[154]. - The ongoing COVID-19 pandemic continues to pose uncertainties, but the company is working to minimize its impact on operations and ensure the availability of pandemic-related medications[155]. Corporate Governance and Management - The company has a dedicated investor relations management team to enhance communication with investors through various channels[175]. - The company adheres to legal and regulatory requirements, ensuring no significant discrepancies in corporate governance practices[175]. - The company has established a clear organizational structure with independent operational departments, ensuring no mixed operations with controlling shareholders[179]. - The management team includes professionals with qualifications such as CPA and advanced degrees, indicating a robust financial oversight[196]. - The company has a strong management team with diverse backgrounds in pharmaceuticals, finance, and law, enhancing its operational capabilities[198]. Sales and Marketing - The sales model primarily utilizes a specialized clinical academic promotion approach, supported by a well-trained sales team across various regions in China[53]. - The company is expanding its market presence by leveraging academic marketing strategies and conducting clinical re-evaluations of its products[71]. - The company will continue to promote its products through academic channels and enhance brand influence and product awareness[151]. Subsidiaries and Partnerships - The subsidiary, Kaibao Health, focuses on product development and market promotion in the health technology sector, aiming to leverage traditional Chinese medicine's unique advantages[46]. - The company has successfully diversified its operations through its subsidiary Shunjie Pharmaceutical, which has obtained necessary licenses for drug and medical device sales[46]. - The company has established partnerships with institutions like Shanghai University of Traditional Chinese Medicine to enhance R&D capabilities[72].

Financial Performance - The company's revenue for Q3 2021 reached ¥256,909,136.47, an increase of 49.19% compared to the same period last year[3] - Net profit attributable to shareholders was ¥33,707,925.29, reflecting a growth of 17.06% year-on-year[3] - The net profit excluding non-recurring gains and losses was ¥28,228,859.31, up by 8.59% from the previous year[3] - Total operating revenue for the period reached ¥794,949,444.36, an increase from ¥647,783,882.97 in the previous period, representing a growth of approximately 22.7%[31] - The net profit for the current period is 115,498,710.67, an increase from 105,737,382.21 in the previous period, representing a growth of approximately 7.4%[34] - The total profit for the current period is 142,151,129.24, compared to 126,614,022.41 in the previous period, reflecting an increase of approximately 12.5%[34] - The company reported a total operating profit of 143,456,457.81, an increase from 129,613,820.45 in the previous period[34] - The company reported a net profit margin improvement, with net profit increasing due to higher revenue and controlled costs[31] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,285,094,604.80, representing a 14.17% increase from the end of the previous year[3] - The total assets increased to ¥3,285,094,604.80 from ¥2,877,284,200.91, marking a growth of around 14.1%[31] - Total liabilities decreased to ¥249,514,010.00 from ¥298,959,816.78, a reduction of approximately 16.6%[31] - The equity attributable to shareholders of the parent company rose to ¥3,035,580,594.80 from ¥2,578,324,384.13, an increase of about 17.7%[31] Cash Flow - The company's cash flow from operating activities showed a net decrease of 52.42%, totaling ¥102,751,921.59 year-to-date[11] - The net cash flow from operating activities is 102,751,921.59, down from 215,975,326.69 in the previous period, indicating a decrease of approximately 52.5%[41] - Cash inflow from investment activities totals 1,462,513,124.76, compared to 2,414,944,920.27 in the previous period, a decrease of about 39.4%[41] - The net cash flow from investment activities is 3,719,861.29, a significant improvement from -104,118,463.44 in the previous period[41] - The cash and cash equivalents at the end of the period amount to 341,816,258.94, up from 98,650,340.02 in the previous period[41] Investments and Acquisitions - The company plans to acquire over 51% of Shanghai Gebaide Biotechnology Co., Ltd. after the completion of Phase III clinical trials for a new drug, with an estimated valuation of RMB 480 million[17] - The company invested RMB 10 million to establish Shanghai Kaihe Jiao Medical Technology Co., Ltd., holding a 75% stake, focusing on chiral materials for medical applications[21] - The company has identified potential risks in a private equity fund investment, estimating a recoverable amount of RMB 15,887,200 based on various scenarios[21] - The company’s investment in the private equity fund totaled RMB 100 million, with RMB 864,000 returned by the end of the third quarter of 2021[21] - The company is in the process of acquiring land use rights, with updates to be disclosed as per regulations[21] Shareholder Information - The company’s major shareholders include Mu Jingwei with 125,873,527 shares and Zhang Yanqi with 160,790,370 shares[15] - The company’s total restricted shares at the end of the period were 129,433,306, with 148,425 shares released during the period[16] Operating Costs and Expenses - The company experienced a 33.31% increase in operating costs year-to-date, attributed to higher sales revenue[10] - Total operating costs amounted to ¥663,967,428.89, up from ¥544,345,297.28, indicating an increase of about 22%[31] - Research and development expenses were ¥31,986,225.60, a decrease from ¥41,170,561.35, reflecting a reduction of approximately 22.2%[31] Other Financial Metrics - The weighted average return on equity for the year-to-date was 4.39%, an increase of 0.30% compared to the previous year[3] - The total comprehensive income for the first nine months of 2021 increased by 362.12%, mainly due to the fair value changes of investments[10] - The company has made strategic investments in long-term equity investments, increasing from ¥248,190,000.00 to ¥621,327,500.00, reflecting a growth of approximately 150%[28] - The cash and cash equivalents amounted to RMB 1,332,194,593.06, while trading financial assets decreased to RMB 68,907,408.67 from RMB 114,647,286.37[22] - Accounts receivable stood at RMB 321,481,008.66, slightly up from RMB 319,556,080.91 in the previous period[22] - Cash and cash equivalents increased significantly, with other current assets rising to ¥10,752,772.18 from ¥1,887,773.21, a growth of approximately 469%[28] - The total comprehensive income attributable to the parent company is 105,737,382.21 for the current period[37] - The basic and diluted earnings per share are both 0.1011[37]

Financial Performance - The company's operating revenue for 2020 was ¥908,008,861.43, a decrease of 36.01% compared to ¥1,419,026,170.35 in 2019[21] - The net profit attributable to shareholders for 2020 was ¥106,122,746.60, down 57.72% from ¥250,986,452.13 in the previous year[21] - The net profit after deducting non-recurring gains and losses was ¥95,675,418.53, a decline of 60.90% compared to ¥244,719,614.36 in 2019[21] - The net cash flow from operating activities was ¥250,649,879.39, a decrease of 24.97% from ¥334,085,296.53 in 2019[21] - The basic earnings per share for 2020 was ¥0.1015, down 57.69% from ¥0.2399 in 2019[21] - The total assets at the end of 2020 were ¥2,877,284,200.91, an increase of 1.22% from ¥2,842,499,295.08 at the end of 2019[21] - The net assets attributable to shareholders at the end of 2020 were ¥2,578,324,384.13, a slight increase of 0.34% from ¥2,569,491,637.53 in 2019[21] - The weighted average return on net assets for 2020 was 4.05%, down from 9.76% in 2019, a decrease of 5.71%[21] Revenue and Sales - The industrial segment accounted for 99.90% of total revenue, with a revenue of ¥907,095,032.36, down 35.99% year-over-year[88] - Injection products generated ¥802,754,175.99, representing 88.41% of total revenue, a decline of 39.34% from ¥1,323,301,090.36 in 2019[85] - Sales volume decreased by 36.16% to 40,550,192 units in 2020 from 63,514,926 units in 2019[89] - The gross profit margin for the industrial segment was 80.28%, down 2.21% from the previous year[88] Research and Development - The company is actively enhancing its R&D capabilities and accelerating the development of new products, particularly in the field of traditional Chinese medicine, in response to national health strategies[53] - The company has received five invention patents, one design patent, and one utility model patent, strengthening its intellectual property protection[67] - R&D investment amounted to ¥59,118,892.81, representing 6.51% of operating revenue, a significant increase from 3.85% the previous year[103] - The proportion of R&D personnel increased to 30.07%, up from 28.66% the previous year[103] - The company has ongoing normal operations with no litigation issues reported[115] Product Development and Market Position - The main product, Tanreqing injection, was included in the clinical treatment guidelines for COVID-19, enhancing its market position and contribution to epidemic prevention[37] - The company has developed a product line focusing on respiratory, cardiovascular, and digestive health, enhancing its competitive edge in the pharmaceutical market[36] - The company’s unique product, Tanreqing capsule, has been included in the national medical insurance directory and recommended for COVID-19 treatment in several provinces, enhancing its market potential[54] - The company is focusing on enhancing its internal management systems to improve decision-making efficiency and operational effectiveness[71] Cash Flow and Investments - The company reported a net increase in cash and cash equivalents of ¥246,471,132.86, a significant improvement of 150.25% compared to the previous year[104] - The net cash flow from investment activities increased by 110.86%, reaching ¥65,213,934.39, primarily due to increased capital recovery[104] - The company made a total investment of ¥90,000,000.00 during the reporting period, a 100% increase from the previous year[112] - The company has allocated CNY 4,350 million for the "Modernization of Traditional Chinese Medicine and Other Pharmaceutical Products Construction Project" as part of the excess fundraising[129] Dividend Policy - The company implemented a cash dividend policy, distributing RMB 0.3 per 10 shares, totaling RMB 31,380,000, which represents 100% of the distributable profit[168] - In 2020, the total cash dividend amounted to RMB 31,380,000, representing 29.57% of the net profit attributable to ordinary shareholders[175] - For 2019, the cash dividend was RMB 104,600,000, which accounted for 41.68% of the net profit attributable to ordinary shareholders[172] Compliance and Governance - The company has adhered to commitments regarding non-competition and related transactions during the reporting period[179] - The integrity status of the company and its controlling shareholders was good, with no unfulfilled court judgments or significant overdue debts[193] - There were no significant lawsuits or arbitration matters during the reporting period[191] - The company has maintained a continuous audit service from domestic accounting firms for 13 years[190] Future Outlook and Strategy - The company plans to enhance its R&D capabilities and accelerate the development of new products, particularly in the field of modern Chinese medicine[150] - The company will continue to explore and develop health-related products, aligning with the national "Healthy China" strategy[152] - The company recognizes the risks associated with the pharmaceutical industry, including policy changes and price control measures, which could impact operations[157] - The company is committed to sustainable development through green production practices and optimizing production processes[154]

上海凯宝药业股份有限公司 2021 年第一季度报告全文 上海凯宝药业股份有限公司 2021 年第一季度报告 2021-012 2021 年 04 月 1 上海凯宝药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人穆竟伟、主管会计工作负责人张育琴及会计机构负责人(会计主 管人员)李雅茹声明：保证季度报告中财务报表的真实、准确、完整。 2 上海凯宝药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ ...

Financial Performance - Operating revenue for the reporting period was ¥172,201,950.77, a decrease of 37.49% year-on-year[9] - Net profit attributable to shareholders was ¥28,795,802.18, down 47.93% compared to the same period last year[9] - Basic earnings per share were ¥0.0275, a decrease of 48.02% compared to the same period last year[9] - Total operating revenue for the current period was ¥172,201,950.77, a decrease of 37.5% compared to ¥275,480,461.94 in the previous period[56] - Net profit for the current period was ¥28,795,802.18, down 47.9% from ¥55,299,739.61 in the previous period[62] - Basic earnings per share for the current period was ¥0.0275, down from ¥0.0529 in the previous period[65] - The total comprehensive income for the current period was ¥28,795,802.18, compared to ¥55,299,739.61 in the previous period[64] - The net profit for the current period is ¥94,447,793.93, down 53.5% from ¥202,754,981.63 in the previous period[86] - The total profit for the current period is ¥111,115,051.69, a decrease of 53.3% compared to ¥236,940,214.58 in the previous period[83] Cash Flow - Net cash flow from operating activities was ¥103,405,287.46, an increase of 110.75% year-on-year[9] - Cash flow from operating activities generated a net amount of ¥215,975,326.69, an increase of 22.5% from ¥176,370,602.62 in the previous period[89] - The net cash flow from operating activities for the current period is ¥203,462,853.27, an increase of 10.6% compared to ¥184,394,212.15 in the previous period[95] - Cash inflow from investment activities totaled ¥2,414,944,920.27, significantly up from ¥869,233,915.65 in the previous period[92] - The net cash flow from investment activities was negative at -¥104,118,463.44, compared to a positive ¥390,157,005.39 in the previous period[92] - Cash flow from financing activities resulted in a net outflow of -¥69,268,592.11, compared to -¥171,758,827.85 in the previous period, indicating improved cash management[99] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,865,226,751.79, an increase of 0.80% compared to the end of the previous year[9] - Total liabilities rose to ¥294,597,732.05, up from ¥273,007,657.55, representing an increase of around 7.9%[49] - Current liabilities decreased to ¥233,792,455.08 from ¥240,023,695.53, a reduction of approximately 2.5%[46] - Non-current assets totaled ¥663,366,982.92, compared to ¥578,819,158.22, indicating an increase of about 14.6%[49] - The company's accounts payable decreased by 44.81% compared to the beginning of the year, primarily due to a reduction in the procurement of raw materials[23] - Total liabilities amounted to CNY 273,007,657.55, with non-current liabilities totaling CNY 32,983,962.02[109] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,282[13] - The top three shareholders held a combined 39.88% of the shares, with Mu Jingwei holding 16.05%[13] - There were no repurchase transactions conducted by the top ten shareholders during the reporting period[20] Government Subsidies and Other Income - The company received government subsidies amounting to ¥15,013,083.11 during the reporting period[9] - Other income increased by 199.70% year-on-year, mainly due to an increase in government subsidies related to daily business activities[24] - Deferred income increased by 117.92% year-on-year, mainly due to an increase in non-recurring government subsidies[23] Research and Development - Research and development expenses increased to ¥17,108,149.46, up 48.5% from ¥11,506,246.51[59] - Research and development expenses for the current period are CNY 41,170,561.35, an increase from CNY 37,634,352.02 in the previous period[73] Tax and Financial Expenses - The company's income tax expense decreased by 42.24% year-on-year, mainly due to a decline in sales revenue[27] - Tax expenses for the current period are CNY 20,876,640.20, down from CNY 36,142,463.38 in the previous period[76] - The company incurred a financial expense of -¥10,633,762.16, an improvement from -¥12,069,159.18 in the previous period[83] Inventory and Current Assets - Inventory was reported at CNY 154,087,957.26, indicating a stable stock position[112] - Current assets totaled CNY 2,017,592,989.97, with cash and cash equivalents at CNY 800,320,107.50[112] Other Financial Metrics - The weighted average return on net assets was 1.13%, down 1.06% year-on-year[9] - The company's retained earnings increased to ¥1,296,084,598.64 from ¥1,294,947,216.43, a slight increase of approximately 0.1%[49] - The total equity attributable to shareholders reached ¥2,570,629,019.74, up from ¥2,569,491,637.53, indicating a marginal increase of about 0.04%[49]